New vaccine aims to better protect blood cancer patients from COVID-19
NCT ID NCT04977024
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new COVID-19 vaccine (GEO-CM04S1) in 63 adults with blood cancers like leukemia or lymphoma who have had a stem cell transplant or cell therapy. The goal is to see if this vaccine triggers a stronger immune response than standard mRNA vaccines, potentially offering better protection against COVID-19. Participants receive two shots and are monitored for immune response and side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COVID-19 INFECTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Atrium Health Wake Forest Baptist
Winston-Salem, North Carolina, 27157, United States
-
City of Hope Medical Center
Duarte, California, 91010, United States
-
Fred Hutchinson Cancer Center
Seattle, Washington, 98109, United States
-
Johns Hopkins University
Baltimore, Maryland, 21205, United States
-
SUNY-Stony Brook
Stony Brook, New York, 11794, United States
-
U Mass Chan Medical School
Worcester, Massachusetts, 01655, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can specially trained immune cells flush out hidden HIV?
- Could muscle loss predict blood cancer outcomes?
- Can a Tumor's DNA guide better cancer care for kids?
- Can a Low-Dose antifungal shield vulnerable patients from deadly fungal infections?
- Frailty check may steer safer cancer care for seniors
- Can engineered immune cells tackle brain lymphoma?